Potently neutralizing human mAbs against the zoonotic pararubulavirus Sosuga virus.
Adaptive immunity
Immunoglobulins
Immunology
Infectious disease
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
24 04 2023
24 04 2023
Historique:
received:
02
11
2022
accepted:
24
02
2023
medline:
25
4
2023
pubmed:
1
3
2023
entrez:
28
2
2023
Statut:
epublish
Résumé
Sosuga virus (SOSV) is a recently discovered paramyxovirus with a single known human case of disease. There has been little laboratory research on SOSV pathogenesis or immunity, and no approved therapeutics or vaccines are available. Here, we report the discovery of human mAbs from the circulating memory B cells of the only known human case and survivor of SOSV infection. We isolated 6 mAbs recognizing the functional attachment protein hemagglutinin-neuraminidase (HN) and 18 mAbs against the fusion (F) protein. The anti-HN mAbs all targeted the globular head of the HN protein and could be organized into 4 competition-binding groups that exhibited epitope diversity. The anti-F mAbs can be divided into pre- or postfusion conformation-specific categories and further into 8 competition-binding groups. The only Ab in the panel that did not display neutralization activity was the single postfusion-specific anti-F mAb. Most of the anti-HN mAbs were more potently neutralizing than the anti-F mAbs, with mAbs in 1 of the HN competition-binding groups possessing ultrapotent (<1 ng/mL) half-maximal inhibitory virus neutralization values. These findings provide insight into the molecular basis for human Ab recognition of paramyxovirus surface proteins and the mechanisms of SOSV neutralization.
Identifiants
pubmed: 36853802
pii: 166811
doi: 10.1172/jci.insight.166811
pmc: PMC10243738
doi:
pii:
Substances chimiques
Antibodies, Monoclonal
0
Viral Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Références
Science. 1993 Nov 26;262(5138):1401-7
pubmed: 8248779
Curr Opin Virol. 2012 Jun;2(3):242-7
pubmed: 22483665
Glycoconj J. 2006 Feb;23(1-2):5-17
pubmed: 16575518
Curr Protoc Microbiol. 2007 Aug;Chapter 14:Unit 14E.2
pubmed: 18770612
J Virol. 1984 Dec;52(3):828-32
pubmed: 6092715
Emerg Infect Dis. 1998 Apr-Jun;4(2):269-71
pubmed: 9621197
J Clin Microbiol. 2018 May 25;56(6):
pubmed: 29643201
J Gen Virol. 2012 Apr;93(Pt 4):850-856
pubmed: 22205718
J Wildl Dis. 2015 Jul;51(3):774-9
pubmed: 25919464
Indian J Med Res. 2016 Jan;143(1):37-42
pubmed: 26997012
J Gen Virol. 2012 May;93(Pt 5):1007-1016
pubmed: 22278823
Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11579-11584
pubmed: 27671656
Adv Virus Res. 2017;98:1-55
pubmed: 28433050
J Virol. 2008 Jan;82(1):565-8
pubmed: 17913804
Curr Opin Virol. 2022 Feb;52:192-202
pubmed: 34954661
Emerg Infect Dis. 2014 Feb;20(2):211-6
pubmed: 24447466
Curr Clin Microbiol Rep. 2016 Sep;3(3):142-154
pubmed: 28138419
J Virol. 1985 Mar;53(3):727-34
pubmed: 3973964
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Infect Dis. 2007 Sep 15;196(6):884-6
pubmed: 17703419
Virus Res. 2001 Apr;74(1-2):133-7
pubmed: 11226581
J Gen Virol. 2019 Mar;100(3):403-413
pubmed: 30688635
Virology. 2015 May;479-480:518-31
pubmed: 25771804
PLoS Pathog. 2018 Feb 22;14(2):e1006837
pubmed: 29470533
Curr Opin Virol. 2014 Apr;5:24-33
pubmed: 24530984
J Virol. 2014 Apr;88(8):3925-41
pubmed: 24453369
PLoS Negl Trop Dis. 2018 Mar 9;12(3):e0006326
pubmed: 29522528
Nat Commun. 2012 Apr 24;3:796
pubmed: 22531181
Viruses. 2020 Jan 30;12(2):
pubmed: 32019182
Nat Commun. 2014 Nov 18;5:5342
pubmed: 25405640
EMBO J. 2001 Aug 1;20(15):4024-34
pubmed: 11483506
Virology. 2007 Mar 15;359(2):436-46
pubmed: 17081582
Science. 1995 Apr 7;268(5207):94-7
pubmed: 7701348
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21514-21520
pubmed: 31591233